A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the correlation between the pharmacokinetic and pharmacodynamic
parameters of CellCept in patients undergoing primary kidney transplantation, in order to
assess the impact on clinical outcome and the risks of acute rejection. All patients will
receive oral CellCept, 1g twice daily, and pharmacokinetic and pharmacodynamic parameters
will be measured at weeks 2, 4, 12 and 24. The anticipated time on study treatment is 24
weeks.